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E-mail address: uhartl@biochem.mpg.de (F.U. HartHuman misfolding diseases arise when proteins adopt non-native conformations that endow them
with a tendency to aggregate and form intra- and/or extra-cellular deposits. Molecular chaperones,
such as Hsp70 and TCP-1 Ring Complex (TRiC)/chaperonin containing TCP-1 (CCT), have been impli-
cated as potent modulators of misfolding disease. These chaperones suppress toxicity of disease pro-
teins and modify early events in the aggregation process in a cooperative and sequential manner
reminiscent of their functions in de novo protein folding. Further understanding of the role of
Hsp70, TRiC, and other chaperones in misfolding disease is likely to provide important insight into
basic pathomechanistic principles that could potentially be exploited for therapeutic purposes.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
A protein must fold into a speciﬁc three-dimensional structure
in order to acquire its functionally active, native state. Although all
information required for achieving the native state is encoded in
the amino acid sequence, the concentrated milieu of the cellular
environment presents challenges to the folding process that are
overcome with the help of cellular machinery termed molecular
chaperones. The cooperative action of molecular chaperones and
the input of metabolic energy allow proteins to avoid aggregation
and efﬁciently reach their native states in vivo [1,2]. However, pro-
teins may misfold or unfold in the face of certain stresses, such as
changes in the cellular environment due to ageing or temperature
ﬂuctuation, genetic mutation, or exposure to amino acid analogues.
The resulting increase in the burden of misfolded or unfolded pro-
teins is normally counterbalanced by quality control machinery,
including chaperones that are activated through the cytosolic
stress pathway, or heat shock response. This pathway, which is
mediated by heat shock transcription factors including HSF-1, re-
sults in nearly-instantaneous induction of expression of genes
encoding chaperones (or heat shock proteins) [3]. Stress-activated
chaperones act as essential modulators of protein homeostasis to
minimize aberrantly folded species by promoting their productive
folding or degradation.chemical Societies. Published by E
yglutamine; TRiC, TCP-1 Ring
l).Unchecked protein aggregation and misfolding are now recog-
nized as the root cause of a large and diverse collection of diseases
termed ‘protein misfolding’ or ‘protein conformational’ disease [4].
These diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer’s, Parkinson’s, Huntington’s and other polyglutamine
diseases, arise when certain proteins adopt non-native conforma-
tions that endow them with a tendency to aggregate and form in-
tra- and/or extra-cellular deposits. In all these cases, protein
misfolding results in ‘gain-of-function’ proteotoxicity, whereby
misfolding confers newly-gained cytotoxicity onto the disease pro-
tein, e.g. by promoting inappropriate interactions that are detri-
mental to the cell (see discussion below). Misfolding and
aggregation of the disease protein may also confer some degree
of loss of function, which may additionally contribute to disease
pathogenesis [5,6].
The aggregation process associated with misfolding disease re-
sults in the formation of homotypic ﬁbrillar aggregates with amy-
loid-like structure, as deﬁned by a ‘cross-b’ core with extensive b-
sheet structure, detergent insolubility, as well as other biochemical
characteristics. Fibrillar aggregates may participate in heterotypic
interactions that result in sequestration of cellular proteins in dis-
ease-speciﬁc deposits (e.g. inclusion bodies, plaques, or Lewy
bodies). These deposits, and the ﬁbrillar aggregates therein, likely
represent ﬁnal manifestations of a multi-step, and perhaps multi-
pathway, aggregation process involving a wide range of stable as
well as metastable intermediates [7–9]. Aggregation intermedi-
ates, or ‘pre-ﬁbrillar’ aggregates, include monomeric and oligo-
meric species that are soluble in nature. Abundant evidence
points towards pre-ﬁbrillar monomers or oligomers as primary
toxic agents underlying misfolding disease, while ﬁbrillarlsevier B.V. All rights reserved.
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15]. For instance, in a neuronal cell model of Huntington’s disease,
cell death correlates with increased levels of diffuse polyglutamine
(polyQ)-expanded huntingtin, the disease protein associated with
Huntington’s disease; whereas inclusion body formation predicts
improved survival [16]. Proteinaceous deposits are also not associ-
ated with toxicity in Parkinson’s and Alzheimer’s disease [16–18].
Furthermore, soluble oligomeric forms of polyQ-expansion pro-
teins, Ab and a-synuclein, the proteins associated with Alzheimer’s
and Parkinson’s disease, respectively, were found to cause toxicity
when added exogenously to cells [15]. Importantly, microinjection
of several different polyQ conformers into mammalian cells indi-
cate that a soluble b-sheet monomer is cytotoxic [10]. However,
rather than a single toxic conformer, it is perhaps more likely that
a range of soluble intermediates exert toxicity, as determined by a
host of factors, including subcellular location, structural, and func-
tional properties of the disease protein [19].
Toxic oligomeric intermediates in misfolding disease may share
structural features critical to the pathogenic process. The anti-oli-
gomer antibody, A11, recognizes a sequence-independent struc-
tural element common to toxic oligomers comprised of Ab, a-
synuclein, prion, and polyQ proteins. A11 was found to block tox-
icity of all these oligomers, indicating that the recognized struc-
tural epitope common to these oligomers is likely directly
involved in aberrant interactions that lead to toxicity [15]. Further-
more, AFM analyses indicate that polyQ-expanded huntingtin, a-
synuclein, and Ab share a propensity to form spherical or ring-like
aggregates that may be on or off-pathway to ﬁbril formation
[14,20]. These shared structural features may indicate a common
pathogenic mechanism underlying misfolding diseases.
Numerous hypotheses have been put forward to account for
neurodegeneration in misfolding disease. Prominent among these
is the ‘‘amyloid pore” hypothesis that poses that ring-like oligo-
meric intermediates exposing hydrophobic regions cause toxicity
by forming pores in cellular membranes [20,21]. Preﬁbrillar species
of a-synuclein and other proteins including Ab and polyQ peptides
have been found to permeabilize membranes under experimental
conditions, lending support to this hypothesis [20,21]. A second
disease mechanism emphasizes aberrant interactions of soluble
intermediates with cellular proteins. Such interactions may inacti-
vate essential cellular factors like TATA-binding protein, or alter
heteroprotein complexes, as has been shown for polyQ-expansion
proteins [5,13,22]. Finally, deﬁcient or non-productive association
of misfolded disease proteins with quality control machinery
may cause general perturbation of cellular protein homeostasis
leading to pathogenesis [23]. The strongest evidence to support
this hypothesis comes from the observation that components of
the quality control system are among the most potent modiﬁers
of disease phenotypes. For the remainder of this review we will fo-
cus on two chaperone classes that have been strongly implicated as
modulators of misfolding disease.2. Chaperones as molecular defenders against misfolding
disease
2.1. The Hsp70 system
Members of the Hsp70 family of molecular chaperones function
in co- and post-translational folding and the quality control of mis-
folded proteins [1,2]. More speciﬁcally, Hsp70s participate in
folding and assembly of newly synthesized proteins into macromo-
lecular complexes; aggregation prevention; dissolution and refold-
ing of aggregated proteins; as well as protein degradation [24].
Hsp70s have an N-terminal ATP-binding domain (NBD) and a C-
terminal substrate-binding domain (SBD) which are both criticalfor chaperone function. Non-native substrates with exposed
hydrophobic stretches within an accessible polypeptide backbone
associate transiently with Hsp70 via its SBD. ATP binding to the
NBD triggers opening of the SBD binding pocket, decreasing afﬁnity
for polypeptide substrates, accelerating both on and off rates.
Reciprocally, substrate binding induces ATP hydrolysis, ‘closing’
the SDB and thus stabilizing the substrate-Hsp70 complex [1,2].
It is this cycle of rapid but controlled binding and release of the
substrate that fosters folding and assembly with partner proteins
while preventing aggregation of substrates; however, detailed
mechanistic understanding of how Hsp70 accomplishes these feats
is not yet available [24]. Generally, it is assumed that an unfolded
protein partitions to the native state upon release from Hsp70;
rebinding of Hsp70 to slow-folding intermediates shields them
from intermolecular interactions, thereby ‘holding’ them in a fold-
ing-competent state and preventing aggregation [1,3,24]. Numer-
ous hypotheses have been put forth to explain the molecular
mechanism of Hsp70-induced structural conversion of substrate
proteins. For example, an ‘entropic pulling’ mechanism has been
proposed, whereby Hsp70 binding stabilizes peptide segments in
an unfolded state, causing local unfolding, thereby facilitating dis-
aggregation and allowing refolding upon Hsp70 release [25].
Co-factors, such as the nucleotide exchange factors (NEFs) and
co-chaperones, are crucial regulatory components of the Hsp70 cy-
cle that confer versatility and speciﬁcity to the Hsp70 chaperone
machine [1,2]. The Hsp40 co-chaperone targets substrates to
Hsp70 while stimulating ATP hydrolysis; NEFs like Bag-1 (BCL2-
associated athanogene 1) and Hsp110 reinitiate the Hsp70 cycle
by facilitating ADP release and rebinding of ATP [24]. Bag-1 has
the additional ability to bind to the 26S proteasome [26]. Another
BAG isoform, the Bag-3 co-chaperone, links Hsp70 to the macro-
autophagic degradation pathway during the ageing process [27].
CHIP (carboxy terminus of HSC70-interacting protein), a co-chap-
erone of Hsp70 that also has E3 ubiquitin ligase activity, cooperates
with Bag-1, and possibly Bag-3, in order to facilitate degradation of
terminally misfolded substrate proteins [28,29]. Studies indicating
that mutations in Hsp70 co-factors are lethal [30–32] or may be
associated with neurodegenerative disease [33] underscore the
importance of regulating the Hsp70 cycle.
Hsp70 has been extensively implicated in the pathogenesis of
misfolding disease [14]. Numerous studies initially found that
Hsp70, other chaperones, and components of the ubiquitin–pro-
teasome system associate with inclusion bodies/plaques character-
istic of misfolding diseases, indicating a general activation of the
cellular quality control machinery in an attempt to circumvent
the accumulation of misfolded species [34]. Further analyses in a
polyglutamine cell culture model using ﬂuorescence imaging re-
vealed that Hsp70 rapidly associates and dissociates with aggre-
gates in a manner similar to interactions between Hsp70 and
unfolded substrates [35]. For unclear reasons, though actively en-
gaged in the task of refolding, the Hsp70 system is ultimately un-
able to refold disease proteins, causing perturbation of protein
homeostasis associated with disease onset. Several hypotheses ac-
count for this apparent imbalance between the production of mis-
folded proteins and Hsp70 activity. The capacity of the Hsp70
system, and the cellular folding environment in general, could sim-
ply be overwhelmed by increasing amounts of misfolded disease
proteins [34,36]. This would be particularly relevant in certain neu-
ronal cell types, which appear to be unable to induce Hsp70
expression above basal levels under stress [37,38]. Progressive
reduction in protein levels and/or activity of Hsp70 and other com-
ponents of the quality control network may exacerbate this imbal-
ance, permitting further accumulation of toxic misfolded proteins.
Such reduction could be due to the ageing process, as transcription
of Hsp70 decreases during ageing of the human brain [39]. The
DNA binding activity of the HSF-1 transcription factor likewise de-
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the ability to induce expression of genes encoding chaperones dur-
ing the cytosolic stress response [40,41]. Consistently, stress-in-
duced expression of Hsp70 is weakened in senescent ﬁbroblasts
[42]. If an age-related decrease in chaperone activity indeed con-
tributes to disease, slowing the ageing process should postpone
or even prevent disease onset, as has been suggested by several
studies in which aggregation-mediated proteotoxicity was amelio-
rated by delaying the ageing process inCaenorhabditis elegansmod-
els of Huntington’s and Alzheimer’s diseases [43–45].
Alternatively, disease processes themselves might cause, or wor-
sen, chaperone deﬁciency. Inclusions have been proposed to
sequester Hsp70 and other proteins in a non-functional state,
inhibiting their essential function in cellular processes [13,34,46].
Additionally, studies report that several cellular models of misfold-
ing diseases do not promptly activate the cytosolic stress response
upon overexpression of disease proteins [47–51]. It is unclear why
cells might fail to activate this critical pathway during disease
pathogenesis; however, this defect might be linked to the known
entrapment and inactivation of key transcription factors in inclu-
sions associated with several misfolding diseases [13,52–55].
Along similar lines, it was recently shown that sequestration of
NF-Y, a regulator of Hsp70 transcription, in huntingtin inclusions
reduces Hsp70 expression in several Huntington’s disease models
[53]. Regardless of whether ageing and/or disease-related pro-
cesses are responsible, levels of Hsp70 are decreased in neurons
most severely affected by disease, arguing that the Hsp70 system
has a key role in regulating neuronal susceptibility to degeneration
[49,50,56].
Counterbalancing the accumulation of misfolded proteins by
overexpressing Hsp70 and/or its co-chaperones suppresses aggre-
gation and toxicity in models of misfolding disease [14,19,57].
For instance, increased Hsp70 levels caused reduced aggregation
and toxicity of tau and Ab, respectively, two components associ-
ated with Alzheimer’s disease [58–60]. Similarly, overexpression
of Hsp70 reduces toxicity and accumulation of a-synuclein in high
molecular weight and detergent-insoluble deposits [61]. Increased
expression of Hsp70 likewise reduced apoptosis and the formation
of co-aggregates between the prion disease protein, PrP, and the
cell death regulator, Bcl-2 [62]. Numerous studies have also shown
that Hsp70 overexpression reduces polyQ toxicity; however, re-
sults are mixed as to whether Hsp70 reduces polyQ inclusion body
formation [14]. In yeast, overexpression of Hsp70 (Ssa1) and Hsp40
(Ydj1) reduces the accumulation of detergent-insoluble ﬁbrillar
aggregates and instead promotes smaller amorphous aggregates
[63], and mutations in these genes were found to speciﬁcally inhi-
bit the accretion of aggregates [64].
Overexpression of Hsp70 co-factors also impacts misfolding dis-
ease proteins. Hsp40 suppresses polyQ inclusion formation and
toxicity in a variety of model systems [65–68]. CHIP suppressed
toxicity of a-synuclein and polyQ proteins, possibly by enhancing
ubiquitination and degradation of oligomers [69–72], although in
at least one instance CHIP reduced the solubility and thus en-
hanced the aggregation of polyQ-expanded ataxin-1 [73]. CHIP
likewise enhances cell survival and accelerates tau and Ab removal
probably by the ubiquitin–proteasome system [74,75]. Bag-1,
which associates with inclusions via interactions with Hsp70, alle-
viates toxicity caused by polyQ-expanded huntingtin fragments
[76]. Hsp110 interacts with and suppresses aggregation of the mu-
tant Cu/Zn superoxide dismutase associated with ALS [77,78], and
furthermore suppresses the aggregation and toxicity of polyQ-ex-
panded androgen receptor, the cause of Kennedy’s disease [79].
Results of in vitro work provide some insight into the mecha-
nism of action of Hsp70 against misfolding and thus toxicity of dis-
ease proteins. Puriﬁed Hsp70 acts preferentially on Ab, huntingtin,
and a-synuclein pre-ﬁbrillar species (i.e. monomers or oligomers,rather than ﬁbrillar aggregates) to modulate the aggregation pro-
cess [8,11,13,80,81]. Hsp70 effectively inhibits the aggregation of
Ab and a-synuclein species even at substoichiometric levels, sug-
gesting that Hsp70 can recognize multimeric protein assemblies
[80,81]. In certain cases, the inﬂuence of Hsp70 on aggregation re-
quires its ATPase activity, and its efﬁcacy is enhanced by the co-
chaperone Hsp40, highlighting the importance of ATP-dependent
cycles of substrate binding and release [8,13,63,80]. On the other
hand, several studies indicate that Hsp70 can strongly inhibit a-
synuclein aggregation in vitro by binding to cytotoxic preﬁbrillar
species, even in the absence of Hsp40 or other co-factors [11,81].
However, Hsp70 function in vivo is likely coupled to co-chaperones
and other co-factors for assistance in binding to aggregating sub-
strates and facilitating their degradation or deposition into inclu-
sion bodies or other assemblies [34]. Substantial progress has
been made regarding the impact of Hsp70 on the aggregation of
polyQ-expanded huntingtin in vitro. In an ATP-dependent manner,
Hsp70/Hsp40 interfere with an intramolecular conformational
change in polyQ-expanded huntingtin that occurs immediately
upon initiation of conditions that favor aggregation, perhaps while
huntingtin is still monomeric [13]. Consistently, Hsp70 together
with Hsp40 was found to stabilize a monomeric huntingtin confor-
mation, and by doing so, prevent the accumulation of spherical and
ring-like oligomers that likely represent toxic species on- or off-
pathway for ﬁbril formation [8]. As a result of the action of
Hsp70/Hsp40 as well as other chaperones, mutant huntingtin is
deviated from the potentially toxic, ﬁbrillar aggregation pathway
and instead accumulates in amorphous aggregates, or other benign
conformers (see discussion below) [8,63,82]. Sequestered in these
conformers, mutant huntingtin may no longer participate in het-
erotypic interactions known to inactivate essential cellular
machinery, such as polyQ-containing transcription factors [13].
It is tempting to speculate about the molecular mechanism of
Hsp70 action on misfolded disease proteins by analogy to its role
in de novo folding (Fig. 1). Considering that Hsp70 generically rec-
ognizes exposed hydrophobic regions in newly-synthesized sub-
strates, it is probable that Hsp70 binds via its SBD to such
regions that may be exposed in a range of preﬁbrillar species, from
monomer to early oligomer [8,11,80,81]. Hsp70 is likely unable to
bind productively to hydrophobic regions that are embedded in ﬁ-
brils occurring late in the aggregation process, and therefore ﬁbrils
are not readily modiﬁed by Hsp70 action [8,11,80,81]. ATP-depen-
dent binding of Hsp70 to monomers/oligomers may induce a struc-
tural change. Binding and release cycles would convert the
structure of the disease protein to one less likely to self-assemble
on a toxic aggregation pathway, and instead more likely to parti-
tion to a non-toxic conformation (e.g. amorphous aggregates,
Fig. 1), or one that is more easily degraded. Recognition and mod-
iﬁcation of toxic pre-ﬁbrillar species by Hsp70 is likely a critical
component of the cellular defense against protein misfolding dis-
ease. Other cellular roles of Hsp70, for instance its known role in
facilitating degradation of misfolded substrates, likely provide
additional neuroprotective effects [14].
2.2. Chaperonins
Chaperonins are a structurally conserved class of molecular
chaperones that are divided into two subgroups [1]. Group I chap-
eronins include the extensively characterized Escherichia coli GroEL
system as well as mitochondrial Hsp60, both of which are essential
for maintaining cellular protein homeostasis. Inactivation of mito-
chondrial Hsp60 via the V98I point mutation severely perturbs this
balance in certain cell types, causing hereditary spastic paraplegia
(SPG13), a late-onset neurodegenerative disease associated with
progressive paraparesis of the lower limbs [83,84]. The Group II
chaperonins, as represented by cytosolic TRiC (TCP-1 Ring Com-
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Fig. 1. A speculative model depicting the role of Hsp70/Hsp40 and TRiC/CCT as modulators of aggregation and toxicity of aberrantly folding disease proteins. Newly
synthesized (or proteolytically generated) disease polypeptides expose hydrophobic regions (blue colored segment). (i) Hsp70/Hsp40 bind to these regions and stabilize the
unfolded substrate. Upon release, partial refolding may allow the polypeptide to achieve a conformation that may be more conducive to interaction with downstream
chaperones, such as TRiC/CCT. (ii) TRiC/CCT may bind to exposed b-strands (green colored segments) and induce a conformational change, leading to the stable formation of
benign, soluble oligomers in the 500 kDa size range, as has been suggested by studies with polyQ proteins. Whether this applies to other proteins of misfolding disease
remains unknown. (iii) When TRiC/CCT levels are limiting, the action of Hsp70/Hsp40 leads to the accumulation of benign amorphous aggregates. (iv) When overall
chaperone levels are inadequate, the newly synthesized (or proteolytically generated) disease polypeptide undergoes an intramolecular compaction in the earliest steps of
the aggregation process, generating a b-structured (green segments) monomer with exposed hydrophobic regions (blue segment). This monomer undergoes ﬁbrillization, a
process that may be inhibited by TRiC/CCT. By virtue of its exposed hydrophobic regions, this monomer may also form 200 kDa soluble ring-like or spherical intermediates,
here depicted as off-pathway for ﬁbril formation, that exert toxicity by interacting with essential cellular machinery or generating membrane pores.
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implicated more extensively in neurodegenerative disease. The
main cellular function of TRiC is to promote the folding of newly-
synthesized polypeptides, which may be presented by Hsp70
and/or the cochaperone prefoldin [1,85]. For this reason, TRiC is
not induced by stress but is instead transcriptionally and function-
ally linked to protein synthesis [86]. TRiC is a large complex com-
posed of eight homologous subunits arranged in two octameric
rings, stacked back-to-back, that form a cage for protein folding
to occur unimpaired by aggregation. Whereas all TRiC subunits
have essentially identical ATPase domains, their polypeptide-bind-
ing regions have signiﬁcantly diverged during evolution to create
substrate binding speciﬁcity [87]. As a result, a diverse set of poly-
peptide substrates, estimated to be 5–10% of newly synthesized
cytoplasmic proteins, including actin and tubulin, ﬂux through
TRiC [1,88,89].
PolyQ-expanded huntingtin has also been identiﬁed as a TRiC
substrate in recent studies [82,90,91]. An RNA interference screen
for suppressors of polyQ aggregation in C. elegans identiﬁed six of
eight TRiC subunits, initially implicating TRiC as an in vivo modu-
lator of polyQ aggregation [92]. Several studies went on to show
that TRiC partially colocalizes with huntingtin aggregates and
remodeled their morphology while reducing cell death [82,91]. It
was also shown that overexpression of subunit 1 of TRiC was effec-
tive at inhibiting huntingtin aggregation and increasing viability[90]. However, knock-down of another subunit (subunit 6), which
impairs the function of the TRiC complex as a whole, increases
huntingtin aggregation and toxicity [85,91]. These results along
with others from yeast studies argue that TRiC as a fully assembled
complex exerts neuroprotective effects by modulating huntingtin
aggregation [82,91].
TRiC substrates tend to be large, hydrophobic proteins with re-
gions of b-strand propensity that are inherently aggregation-prone
[88,93–96]. Consistently, polyQ-expanded huntingtin, as well as all
other amyloidogenic proteins, tend to form ﬁbrillar aggregates
possessing a ‘cross-b’ core with extensive b-sheet structure [4].
Moreover, the aggregation pathway of these proteins begins by a
rapid conformational transition from native monomer into a com-
pact b-sheet structure necessary for the formation of mature amy-
loid ﬁbrils [13,34,82]. It is therefore plausible that TRiC regulates
the conformation of huntingtin and possibly other amyloidogenic
proteins by binding directly to b-sheet structures formed after
aggregation initiation, potentially directly after synthesis or prote-
olytic generation of aggregation prone fragments (Fig. 1).
Optimal protection by TRiC requires prior processing by the
Hsp70 machinery in a cooperative reaction similar to de novo fold-
ing of certain substrates [1,82]. TRiC/Hsp70 were found to act in
concert on huntingtin monomers or small oligomers early in the
aggregation pathway to promote the formation of non-pathogenic
oligomers of 500 kDa and reduce levels of 200 kDa oligomers
S.A. Broadley, F.U. Hartl / FEBS Letters 583 (2009) 2647–2653 2651that are reactive with the A11 antibody and appear to be associated
with polyQ toxicity [82]. Chaperone-assisted folding and aggrega-
tion reactions mediated by Hsp70/TRiC therefore share intriguing
features. In both cases, Hsp70 ﬁrst interacts with the substrate to
stabilize it in a conformation conducive to interaction with TRiC,
the downstream factor which subsequently promotes folding to
the native or non-pathogenic state. Furthermore, in both de novo
folding and aggregation reactions, Hsp70/TRiC act at critical early
steps to ensure productive (or protective) folding of the polypep-
tide substrate. Thus, basic principles of chaperone cooperation be-
tween Hsp70 and TRiC used in de novo protein folding are also
employed in the cellular defense mechanism against amyloido-
genic proteins.3. Concluding remarks
Based on aforementioned principles of de novo folding and pro-
tein aggregation, a speculative model of chaperone-mediated
aggregation in misfolding disease is proposed (Fig. 1). Newly syn-
thesized or proteolytically generated disease proteins may expose
hydrophobic regions, which are soon bound by the Hsp70/Hsp40
machinery early in the aggregation process. Upon release from
Hsp70, refolding may bury hydrophobic regions and/or allow the
disease polypeptide to achieve a conformation that may be more
conducive to interaction with downstream chaperones. According
to studies with polyQ-expansion proteins, the disease polypeptide
is then either deposited into benign amorphous inclusions or fur-
ther modiﬁed by the TRiC chaperonin [63,82]. TRiC may bind to ex-
posed b-strands and induce a conformational change in the disease
protein that promotes its stable accumulation in soluble oligomers
of 500 kDa, as has been shown for polyQ-expanded huntingtin
fragments [13]. Whether this part of the pathway applies to other
disease proteins is currently unknown. When overall chaperone
levels are inadequate, the newly synthesized (or proteolytically
generated) disease polypeptide undergoes an intramolecular struc-
tural change in the earliest steps of the aggregation process [13],
generating a b-structured monomer with exposed hydrophobic re-
gions. By virtue of these hydrophobic regions, the monomer may
accumulate in ring-like or spherical intermediates on- or off-path-
way for ﬁbril formation, that exert toxicity by generating mem-
brane pores or inactivating essential cellular factors [8,13,82].
Such structures have been reported in models of Huntington’s, Par-
kinson’s, and Alzheimer’s disease and proposed to be primary
agents of toxicity in the pathogenesis of misfolding disease [14].
Monomers may also accumulate in long ﬁbrillar structures in a
process that may be inhibited by TRiC, as has been described for
polyQ aggregation [82]. Amyloid ﬁbrils that form late in the aggre-
gation process collect in inclusions, plaques, or Lewy bodies in
brain tissue and are not modiﬁed readily by chaperone function
[8,11,13,80,81].
Given the protective effects of overexpressing chaperones in
models of misfolding disease, it is probable that drug-mediated
enhancement of chaperone levels would be a effective strategy
for delaying or even preventing misfolding disease. Promising re-
sults have been reported for geldanamycin (GA) and its derivatives
17-AAG and 17-DMAG, which inhibit Hsp90 by binding to its N-
terminal ATP-binding pocket, resulting in HSF-1 stimulation and
induction of stress protein expression [57,97]. These inhibitors
are broadly effective against aggregation and toxicity in various
model systems of misfolding disease [17,50,98–100]. However, a
possible problem with developing these inhibitors for human use
is their potential to elicit side effects, which stem from inhibition
of Hsp90 [57]. Indeed, results from clinical trials evaluating the ef-
fect of geldanamycin analogues on cancer suggest no efﬁcacy at
doses with acceptable toxicity [101,102]. Another Hsp90 inhibitor,novobiocin, may prove to be a more useful therapeutic agent.
Novobiocin, a coumarin-containing DNA gyrase inhibitor, binds in-
stead to the C-terminal domain of Hsp90 and causes no apparent
cytotoxicity at doses found to elevate Hsp70 expression. Novobio-
cin and its derivatives were reported to suppress Ab neurotoxicity,
suggesting they may be optimal candidates for clinical testing with
patients with misfolding disease [103]. Conditions such as caloric
restriction, which stimulate HSF-1 through other mechanisms
may also prove useful. Stress due to moderate caloric restriction in-
duces known beneﬁcial effects, like life-span extension, in part by
activating the deacetylase SIRT1 [104]. It has recently come to light
that SIRT1 activates HSF1, thereby enhancing the transcription of
target chaperone genes such as Hsp70 upon exposure to stress
[105]. Caloric restriction or chemical activators of SIRT1 (e.g. by
resveratrol) likely provide a means to enhance levels of Hsp70
and other chaperones while promoting longevity and potentially
delaying or preventing disease onset. Caloric restriction and resve-
ratrol indeed improve phenotypes in misfolding disease models,
and their effect on Alzheimer’s disease patients is currently being
evaluated in clinical trials [104]. Other drug candidates that stim-
ulate HSF-1 include arimoclomol and celastrol, both of which were
found to improve misfolding disease phenotypes in model systems
[106,107]. These and other methods that result in induction of
expression of Hsp70 and other chaperones associated with the
cytosolic stress response hold great promise as therapeutic agents.
In principle, drug-mediated induction of the TRiC chaperonin
would be another worthy therapeutic strategy; however, almost
nothing is known about the regulation of the TRiC chaperonin
and therefore efforts in this direction have so far not been fruitful.
While it remains to be seen whether patients will eventually ben-
eﬁt from these types of approaches, a better understanding of the
role of Hsp70, TRiC, and other chaperones in misfolding disease is
likely to provide important insight into basic pathomechanistic
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